Summary part 1: 46% of psoriasis patients say that
Post# of 72440
Page 14, patients are discouraged -- 55% think that it's not realistic to hope for a clearing of the condition.
Page 17 PATENT PENDING on Prurisol manufacturing process. Did we know that already?
Page 24 (we knew this but newer people here might not)
Quote:
Had one site,
where investigator non-compliance was suspected to have occurred been removed from overall data analyses, 43% of patients in the 200mg
dosing arm would have met the primary endpoint.
and details on the next clinical trial:
Quote:
• In the second half of 2016, Cellceutix plans to initiate a Phase 2b trial of Prurisol, testing higher dosing regimens (300mg and 400mg arms),
for the treatment of moderate-to-severe psoriasis. The company also is exploring Prurisol’s use in treating eczema.